By developing your antibody drug conjugate (ADC), you’re helping advance medical treatment in revolutionary ways. These novel biotherapies that link monoclonal antibodies to deliver highly potent active pharmaceutical ingredients (HPAPIs) are inherently complex, but they can be very effective for targeting unhealthy cells. To ensure the safety and effectiveness of your ADC, it’s imperative to characterize your biotherapy to confirm its structure, binding, purity, and potency.

Partner with us to get expert guidance on the biological components of your ADC, both the ‘naked’ antibody and
the drug-conjugated antibody. We work with you to de-risk the development and manufacturing process by providing
safer, reliable, and faster testing, expediting product quality decisions at critical junctures.

You’ll have access to:

• GMP compliant laboratories
• Up-to-date regulatory advice and oversight
• Cutting-edge technology and equipment
• Experienced scientists and a dedicated project management team

The primary mechanism of action (MoA) for ADCs is direct cytotoxicity through intracellular release of a toxin following specific binding to target tumor antigen. However, understanding the role of the antibody in directing an ADC to tumor cells and the potential for immune recruitment as a secondary contributing MoA reinforces the importance of understanding:

• Antibody structure–function relationship
• Desired quality attributes for its chosen application
• Binding to the target antigen
• Cytotoxic activity
• Impact on efficacy following conjugation
• Functionality following conjugation
• Choice of linker used or the method of conjugation